

# Sonia M Vallabh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9011871/publications.pdf>

Version: 2024-02-01

16  
papers

966  
citations

933447

10  
h-index

940533

16  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1718  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying prion disease penetrance using large population control cohorts. <i>Science Translational Medicine</i> , 2016, 8, 322ra9.	12.4	289
2	Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides. <i>Biomolecules</i> , 2020, 10, 1.	4.0	186
3	Antisense oligonucleotides extend survival of prion-infected mice. <i>JCI Insight</i> , 2019, 4, .	5.0	80
4	Age at onset in genetic prion disease and the design of preventive clinical trials. <i>Neurology</i> , 2019, 93, e125-e134.	1.1	73
5	Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. <i>Nucleic Acids Research</i> , 2020, 48, 10615-10631.	14.5	69
6	Towards a treatment for genetic prion disease: trials and biomarkers. <i>Lancet Neurology</i> , The, 2020, 19, 361-368.	10.2	60
7	Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. <i>Human Molecular Genetics</i> , 2015, 24, 2442-2457.	2.9	53
8	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7793-7798.	7.1	41
9	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. <i>BMC Medicine</i> , 2020, 18, 140.	5.5	34
10	Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 2388-2400.	3.8	22
11	Multimodal small-molecule screening for human prion protein binders. <i>Journal of Biological Chemistry</i> , 2020, 295, 13516-13531.	3.4	14
12	Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS. <i>JCI Insight</i> , 2022, 7, .	5.0	11
13	Genetic counseling for prion disease: Updates and best practices. <i>Genetics in Medicine</i> , 2022, 24, 1993-2003.	2.4	11
14	Novel quaternary structures of the human prion protein globular domain. <i>Biochimie</i> , 2021, 191, 118-125.	2.6	4
15	The Patient-Scientistâ€™s Mandate. <i>New England Journal of Medicine</i> , 2020, 382, 107-109.	27.0	3
16	Implications of new genetic risk factors in prion disease. <i>Nature Reviews Neurology</i> , 2021, 17, 5-6.	10.1	1